

ASX Announcement

Investor Webinar Presentation

Sydney Australia, 17 March 2026: Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) (**Recce or the Company**), the Company developing a New Class of Synthetic Anti-Infectives is pleased to announce a live online webinar.

The event will be held online via Zoom on **19 March 2026 at 10:30AM AEDT** and will be recorded for those who cannot attend.

The webinar will feature presentations from experts across key program areas, including the Company's Registrational Phase 3 Clinical Trial for Diabetic Foot Infections in Indonesia and its U.S. Department of War burn wound program. Presenters will also provide updates on Recce's broader anti-infective portfolio, covering both clinical and pre-clinical programs, together with other operational highlights.

A copy of the presentation slides will be made available via the ASX prior to the online webinar and a full recording made available via Recce Pharmaceuticals' website following the event.

To attend the webinar, please register using the link below:

https://us02web.zoom.us/webinar/register/WN_pfiXi_ccSjGfmEP6OW5R4g

This announcement has been approved for release by Recce Pharmaceuticals Board.



ASX: RCE, **FSE:** R9Q

Head Office: Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 **T** +61 (2) 9000 1907

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA